These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33307863)

  • 1. How can we improve the design of small molecules to target thioredoxin reductase for treating cancer?
    Xu J; Fang J
    Expert Opin Drug Discov; 2021 Apr; 16(4):331-333. PubMed ID: 33307863
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting thioredoxin reductase: anticancer agents and chemopreventive compounds.
    Zeng HH; Wang LH
    Med Chem; 2010 Sep; 6(5):286-97. PubMed ID: 20977412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thioredoxin reductase inhibitors: a patent review.
    Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
    Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibitors of mammalian thioredoxin reductase.
    Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
    Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Thioredoxin System for Cancer Therapy.
    Zhang J; Li X; Han X; Liu R; Fang J
    Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.
    Liu X; Pietsch KE; Sturla SJ
    Chem Res Toxicol; 2011 May; 24(5):726-36. PubMed ID: 21443269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.
    He J; Li D; Xiong K; Ge Y; Jin H; Zhang G; Hong M; Tian Y; Yin J; Zeng H
    Bioorg Med Chem; 2012 Jun; 20(12):3816-27. PubMed ID: 22579620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioredoxin reductase inhibitors: updated patent review (2017-present).
    Chupakhin E; Krasavin M
    Expert Opin Ther Pat; 2021 Aug; 31(8):745-758. PubMed ID: 33666133
    [No Abstract]   [Full Text] [Related]  

  • 9. Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update.
    Zhang J; Zhang B; Li X; Han X; Liu R; Fang J
    Med Res Rev; 2019 Jan; 39(1):5-39. PubMed ID: 29727025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual screening-guided discovery of thioredoxin reductase inhibitors.
    Liu R; Shi D; Zhang J; Li X; Han X; Yao X; Fang J
    Toxicol Appl Pharmacol; 2019 May; 370():106-116. PubMed ID: 30898620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecules to Target the Selenoprotein Thioredoxin Reductase.
    Zhang B; Liu Y; Li X; Xu J; Fang J
    Chem Asian J; 2018 Dec; 13(23):3593-3600. PubMed ID: 30204305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.
    Gandin V; Fernandes AP
    Molecules; 2015 Jul; 20(7):12732-56. PubMed ID: 26184149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
    Powis G; Wipf P; Lynch SM; Birmingham A; Kirkpatrick DL
    Mol Cancer Ther; 2006 Mar; 5(3):630-6. PubMed ID: 16546977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Thioredoxin Reductase by Triosmium Carbonyl Clusters.
    Koh WX; Coppo L; Holmgren A; Kong JW; Leong WK
    Chem Res Toxicol; 2020 Sep; 33(9):2441-2445. PubMed ID: 32786549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
    Liu Y; Li Y; Yu S; Zhao G
    Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
    Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
    Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells.
    Engman L; Kandra T; Gallegos A; Williams R; Powis G
    Anticancer Drug Des; 2000 Oct; 15(5):323-30. PubMed ID: 11354308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and SAR of Withangulatin A Analogues that Act as Covalent TrxR Inhibitors through the Michael Addition Reaction Showing Potential in Cancer Treatment.
    Wang C; Li S; Zhao J; Yang H; Yin F; Ding M; Luo J; Wang X; Kong L
    J Med Chem; 2020 Oct; 63(19):11195-11214. PubMed ID: 32886510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thioredoxin reductase as a novel molecular target for cancer therapy.
    Nguyen P; Awwad RT; Smart DD; Spitz DR; Gius D
    Cancer Lett; 2006 May; 236(2):164-74. PubMed ID: 15955621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells.
    Viry E; Battaglia E; Deborde V; Müller T; Réau R; Davioud-Charvet E; Bagrel D
    ChemMedChem; 2008 Nov; 3(11):1667-70. PubMed ID: 18759235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.